-
William Blair Coughs Up $4.5 Million In SEC Settlement
Wednesday, May 3, 2017 - 12:25pm | 200Following a Securities and Exchange Commission investigation of a four-year span of fund management, William Blair & Company agreed this week to pay $4.5 million to settle claims of improper fund distribution. The SEC accused William Blair in an earlier administrative order of blowing about $1....
-
Shocker: Life-Saving Portable Defibrillator Movement Plagued By Malfunctions
Thursday, March 30, 2017 - 3:49pm | 2393Portable defibrillators seem so commonplace these days that people in danger of heart failure can buy one online for about $1,200. But the two-decade movement to make the life-saving devices as handy as fire extinguishers is all but flatlining. Some analysts say the explosive growth that triggered...
-
Here's Why Chipotle Looks Poised To Beat Expectations
Friday, April 17, 2015 - 10:17am | 201William Blair issued a report on Chipotle Mexican Grill, Inc. (NYSE: CMG) ahead of Chipotle’s earnings announcement on April 21. William Blair rates Chipotle as Outperform, while a price target is unavailable. Analysts Sharon Zackifia and Tania Anderson wrote, “We expect Chipotle...
-
Under Armour Suits Up For Stock Split
Monday, March 17, 2014 - 1:07pm | 488On Monday, Under Armour, Inc. (NYSE: UA) announced that the Board of Directors approved a two-for-one stock split. The press release stated that the stock split will work as dividend, giving stockholders on record on March 28, 2014 one share of Class A Common Stock for each Class A Common Stock...
-
William Blair Sees Significant Opportunity for LinkedIn to Grow in Emerging Markets
Tuesday, December 10, 2013 - 1:00pm | 178In a report published Tuesday, William Blair & Company analyst Timothy McHugh reiterated a Market Perform rating on LinkedIn Corp. (NYSE: LNKD). In the report, William Blair & Company noted, “A significant part of LinkedIn's long-term growth story is dependent on international expansion,...
-
UPDATE: William Blair & Company Upgrades Sonic Following Investor Meetings with Management
Wednesday, December 4, 2013 - 1:02pm | 143In a report published Wednesday, William Blair & Company analyst Sharon Zackfia upgraded the rating on Sonic (NASDAQ: SONC) from Market Perform to Outperform. In the report, William Blair & Company noted, “We recently hosted investor meetings with Sonic's management team and came away with...
-
UPDATE: William Blair & Company Upgrades WABCO on Multiple Positive Factors
Tuesday, December 3, 2013 - 10:32am | 254In a report published Tuesday, William Blair & Company analyst Lawrence De Maria upgraded the rating on WABCO Holdings (NYSE: WBC) from Market Perform to Outperform, and raised the price target from $90.00 to $105.00. In the report, William Blair & Company noted, “We view Wabco as a...
-
Starbucks Looks Toward Franchise Strategy to Caffeinate European Business
Monday, December 2, 2013 - 2:22pm | 276Starbucks (NASDAQ: SBUX) is looking to franchise European cafes to perk up business, according to the Wall Street Journal. Starbucks has avoided franchising in an attempt to better control the brand, opening its first franchise-owned store this past February in the United Kingdom. The company...
-
UPDATE: William Blair & Company Initiates Coverage on Zoetis on Good Earnings Growth Potential
Monday, November 25, 2013 - 12:01pm | 167In a report published Monday, William Blair & Company analyst Margaret Kaczor initiated coverage on Zoetis (NYSE: ZTS) with a Market Perform rating. In the report, William Blair & Company noted, “We are initiating coverage of ZTS with a Market Perform rating and Established Growth company...
-
UPDATE: William Blair & Company Initiates Coverage on Criteo SA on Positive Outlook
Monday, November 25, 2013 - 12:00pm | 125In a report published Monday, William Blair & Company analyst Justin Furby initiated coverage on Criteo SA (NASDAQ: CRTO) with an Outperform rating. In the report, William Blair & Company noted, “CRTO enables e-commerce companies to remind consumers about items they previously showed...
-
UPDATE: William Blair & Company Downgrades GSE Holding Following Below-Expectations 3Q 2013 Revenue/Earnings
Monday, November 18, 2013 - 11:21am | 114In a report published Monday, William Blair & Company analyst Brian Drab downgraded the rating on GSE Holding (NYSE: GSE) from Outperform to Market Perform. In the report, William Blair & Company noted, “GSE reported third quarter 2013 revenue and earnings that came in below expectations....
-
William Blair & Company Reiterates on 3D Systems Following Recovery After 3Q Report
Tuesday, November 12, 2013 - 11:25am | 183In a report published Tuesday, William Blair & Company analyst Brian Drab reiterated an Underperform rating on 3D Systems (NYSE: DDD). In the report, William Blair & Company noted, “3D Systems reported third-quarter results on October 29, 2013. The stock is up 34% since the report (closed...
-
William Blair Reiterates Outperform on Teradata Following Preliminary 3Q Results
Tuesday, October 15, 2013 - 11:12am | 155In a report published Tuesday, William Blair & Company analyst Bhavan Suri reiterated an Outperform rating on Teradata Corporation (NYSE: TDC). In the report, William Blair & Company noted, “Monday evening, Teradata released preliminary third quarter 2013 results that were well below the...
-
William Blair Reiterates Outperform Rating on Facebook Following Company/Investor Meetings
Friday, October 4, 2013 - 10:37am | 84In a report published Friday, William Blair & Company analyst Ralph Schackart reiterated an Outperform rating on Facebook (NASDAQ: FB). In the report, William Blair & Company noted, “Over the past few weeks, we spoke with several private companies and advertisers about their experiences...
-
William Blair Reiterates Outperform on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss
Friday, September 27, 2013 - 11:14am | 149In a report published Friday, William Blair & Company analyst John Sonnier reiterated an Outperform rating on Nektar Therapeutics (NASDAQ: NKTR). In the report, William Blair & Company noted, “Although NKTR-181 demonstrated analgesic properties in the Phase II trial, we acknowledge the...